Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Jatin J. Shah, Lei Feng, MS, Elisabet E. Manasanch, MD, Donna M. Weber, MD, Sheeba K. Thomas, MD, Francesco Turturro, MD, Raymond Alexanian, MD, Nina Shah, Uday R. Popat, MD, Yago Nieto, Qaiser Bashir, Muzaffar H. Qazilbash, Richard E Champlin, MD, Robert Z. Orlowski, MD, PhD

Blood (2014) 124 (21): 33.

https://doi.org/10.1182/blood.V124.21.33.33

Published: 2014

Journal Articles

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Jatin J. Shah, M.D., Aparna Hegde, MD, Xiao Zhou, MD, PHD, Sheeba K. Thomas, MD, Michael Wang, MD, Donna M. Weber, M.D., Raymond Alexanian, MD, Robert Z. Orlowski, MD, PhD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 2244.

https://doi.org/10.1182/blood.V120.21.2244.2244

Published: 2012

Journal Articles

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, MD, Michael Wang, MD, Sheeba Thomas, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday Popat, MD, Donna Weber, MD

Blood (2010) 116 (21): 1948.

https://doi.org/10.1182/blood.V116.21.1948.1948

Published: 2010

Journal Articles

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom’s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Ronjay Rakkhit, MD, Kay B Delasalle, B.S., Maria B. Gavino, R.N., Sheeba K. Thomas, Meletios A Dimopoulos, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Peter McLaughlin, MD, Raymond Alexanian, MD, Donna M. Weber, MD

Blood (2008) 112 (11): 3065.

https://doi.org/10.1182/blood.V112.11.3065.3065

Published: 2008

Journal Articles

Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Lenalidomide-Dexamethasone (BLD).

Michael Wang, MD, Kay Delasalle, Sergio Giralt, MD, Raymond Alexanian, MD

Blood (2007) 110 (11): 3611.

https://doi.org/10.1182/blood.V110.11.3611.3611

Published: 2007

Journal Articles

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Jennifer A. Wright, MD, Donna Weber, MD, Sheeba K. Thomas, MD, Michael Wang, MD, Raymond Alexanian, MD, Victoria E. Hawkins, DRPH, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 1882.

https://doi.org/10.1182/blood.V110.11.1882.1882

Published: 2007

Journal Articles

Trend and Geographic Variations in the Incidence of Waldenstrom’s Macroglobulinemia in the United States over 17 Years from 1988 to 2004.

Michael Wang, MD, Yuhong Zhou, MD, Haijun Wang, MD, Qing Yi, MD, PhD, Yanxia Zhang, MD, Raymond Alexanian, MD, Larry Kwak, MD, Ph.D., Xin Du, MD, PhD

Blood (2007) 110 (11): 5174.

https://doi.org/10.1182/blood.V110.11.5174.5174

Published: 2007

Journal Articles

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Sergio A. Giralt, MD, Sheeba K. Thomas, MD, Raymond Alexanian, MD, Xiao Zhou, MD, Priya Patel, BS, Carlos E. Bueso-Ramos, MD, PHD, Robert A. Newman, PHD, MS, Bharat B. Aggarwal, PHD, MS

Blood (2007) 110 (11): 1177.

https://doi.org/10.1182/blood.V110.11.1177.1177

Published: 2007

Journal Articles

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Sergio Giralt, MD, Rupi Thandi, MD, Muzaffar Qazilbash, MD, Floralyn Mendoza, BS, Eric Han, BS, Chitra Hosing, MD, Michael Wang, MD, Sheeba Thomas, MD, Raymond Alexanian, MD, Richard Champlin, MD, Donna Weber, MD

Blood (2007) 110 (11): 948.

https://doi.org/10.1182/blood.V110.11.948.948

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael Wang, MD, Robert Knight, MD, Melitios Dimopoulos, MD, David Siegel, MD, S. Vincent Rajkumar, MD, Thierry Facon, MD, Raymond Alexanian, MD, Zhinuan Yu, PhD, Jerome Zeldis, MD, PhD, Marta Olesnyckyj, Donna Weber, MD

Blood (2006) 108 (11): 3553.

https://doi.org/10.1182/blood.V108.11.3553.3553

Published: 2006

Journal Articles

Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma.

Michael Wang, MD, Kay Delasalle, Sheeba Thomas, MD, Sergio Giralt, MD, Raymond Alexanian, MD

Blood (2006) 108 (11): 403.

https://doi.org/10.1182/blood.V108.11.403.403

Published: 2006

Journal Articles

A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Michael Wang, MD, Moshe Talpaz, MD, Sundar Jagannath, MD, Asher Alban Chanan-Khan, MD, Raymond Alexanian, MD, Donna M. Weber, MD, Maria Gavino, R.N., Zeev Estrov, MD, Pamela J. Harris, MD, Donald Picker, MD, Robert L. Schlossman, MD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 111.

https://doi.org/10.1182/blood.V106.11.111.111

Published: 2005

Journal Articles

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Anna Christoforidou, MD, Patricia Williams, RN, Linda Roden, MD, Ana Aleman, MD, Donna Weber, MD, Floralyn Mendoza, BS, Donald Podoloff, MD, Hazel Breitz, MD, Raymond Alexanian, MD, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 426.

https://doi.org/10.1182/blood.V106.11.426.426

Published: 2005

Journal Articles

Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy.

Michael Wang, MD, Kay Delasalle, Sergio Giralt, MD, Raymond Alexanian, MD

Blood (2005) 106 (11): 784.

https://doi.org/10.1182/blood.V106.11.784.784

Published: 2005

Journal Articles

VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

Luhua M. Wang, MD, Donna M. Weber, MD, Kay B. Delasalle, Raymond Alexanian, MD

Blood (2004) 104 (11): 210.

https://doi.org/10.1182/blood.V104.11.210.210

Published: 2004

Journal Articles

2-Chlorodeoxyadenosine (2-CdA) and Cyclophosphamide (Cy) Alone or in Combination with Rituximab (Rit) for Previously Untreated Waldenstrom’s Macroglobulinemia (WM).

Donna M. Weber, MD, Michael Wang, MD, Kay B. Delasalle, BS, Maria Gavino, RN, Raymond Alexanian, MD

Blood (2004) 104 (11): 1476.

https://doi.org/10.1182/blood.V104.11.1476.1476

Published: 2004

Journal Articles

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow in Previously Untreated Patients with Multiple Myeloma.

Lia Angela Moulopoulos, MD, Dimitra Gika, MD, Kay Dellasale, Donna Weber, MD, Athanasios Anagnostopoulos, MD, Raymond Alexanian, MD, Meletios A. Dimopoulos, MD

Blood (2004) 104 (11): 1485.

https://doi.org/10.1182/blood.V104.11.1485.1485

Published: 2004

NARROW

Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom’s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Lenalidomide-Dexamethasone (BLD).

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Trend and Geographic Variations in the Incidence of Waldenstrom’s Macroglobulinemia in the United States over 17 Years from 1988 to 2004.

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma.

A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy.

VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

2-Chlorodeoxyadenosine (2-CdA) and Cyclophosphamide (Cy) Alone or in Combination with Rituximab (Rit) for Previously Untreated Waldenstrom’s Macroglobulinemia (WM).

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow in Previously Untreated Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only